Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Dec 26;14(12):e0226339.
doi: 10.1371/journal.pone.0226339. eCollection 2019.

Comparison of 6-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants in the era of lifelong ART: Results from an observational prospective cohort study

Appolinaire Tiam  1   2 , Seble G Kassaye  3 , Rhoderick Machekano  1 , Vincent Tukei  4 , Michelle M Gill  1 , Majoalane Mokone  4 , Mosilinyane Letsie  5 , Mots'oane Tsietso  5 , Irene Seipati  5 , Janety Barasa  4 , Anthony Isavwa  4 , Thorkild Tylleskär  2 , Laura Guay  1   6
Affiliations
Observational Study

Comparison of 6-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants in the era of lifelong ART: Results from an observational prospective cohort study

Appolinaire Tiam et al. PLoS One. .

Abstract

Background: Lifelong antiretroviral therapy (ART) reduces mother-to-child HIV transmission (MTCT) and improves maternal health. Data on the outcomes of HIV-exposed infants (HEI) compared to their unexposed counterparts in the era of universal ART is limited. We compared birth and 6-week outcomes among infants born to HIV-positive and HIV-negative women in Lesotho.

Methods: 941 HIV-negative and 653 HIV-positive pregnant women were enrolled in an observational cohort to evaluate the effectiveness of prevention of mother-to-child HIV transmission (PMTCT) program after implementation of universal maternal ART in 14 health facilities. Pregnancy, delivery, birth, and 6-week data were collected through participant interviews and medical record review. DNA PCR testing for HEI was conducted within 2 weeks of birth and at around 6 weeks of age. Data were analysed to estimate the distribution of birth outcomes, mortality, HIV transmission and HIV-free survival at 6 weeks.

Results: HIV-positive women were older (mean age of 28.7 vs. 24.4 years) and presented for antenatal care earlier (mean gestational age of 23.0 weeks vs 25.3 weeks) than HIV-negative women. Prematurity was more frequent among HEI, 7.8% vs. 3.6%. There was no difference in rates of congenital anomalies between HEI (1.0%) and HIV-unexposed infants (HUI) (0.6%). Cumulative HIV transmission was 0.9% (N = 4/431) (95% CI:0.25-2.36) at birth and 1.0% (N = 6/583) (95% CI:0.38-2.23) at 6 weeks. Overall mortality, including stillbirths, was 5.2% and 6.0% by 6 weeks for HUI and HEI respectively. Among liveborn infants, 6-week HIV-free survival for HEI was 95.6% (95% CI:93.7-97.1) compared to 96.8% (95% CI:95.4-97.9) survival for HUI.

Conclusions: Implementation of universal maternal ART lowers MTCT at 6 weeks of age with no differences in congenital anomalies or early mortality between HIV exposed Infants and HIV unexposed infants. However, HIV exposed infants continue to have high rates of prematurity despite improved maternal health on ART.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist

Figures

Fig 1
Fig 1. Study enrollment for comparison of 6-week PMTCT outcomes for HEI and HUI in the era of lifelong ART.
Fig 2
Fig 2. Survival of HUI and HEI at six weeks of age including and excluding stillbirths.
See this image and copyright information in PMC

References

    1. The Kingdom Of Lesotho, Government of Lesotho. Final Report for a Joint Review of HIV/Tuberculosis and Hepatitis Programmes. 2 December, 2017. Available from: http://www.unaids.org/sites/default/files/country/documents/LSO_2018_cou.... Cited 2 January 2019.
    1. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3): 171–80. 10.1016/S1473-3099(10)70288-7 - DOI - PubMed
    1. Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: A cohort study. J Infect Dis. 2016;213(7): 1057–64. 10.1093/infdis/jiv389 - DOI - PubMed
    1. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11): 1695–1705. 10.1093/infdis/jis553 - DOI - PMC - PubMed
    1. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis. 2012;206(11): 1639–1641. 10.1093/infdis/jis581 - DOI - PMC - PubMed

Publication types

MeSH terms